Your browser doesn't support javascript.
loading
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Loi, Sherene; Giobbie-Hurder, Anita; Gombos, Andrea; Bachelot, Thomas; Hui, Rina; Curigliano, Giuseppe; Campone, Mario; Biganzoli, Laura; Bonnefoi, Hervé; Jerusalem, Guy; Bartsch, Rupert; Rabaglio-Poretti, Manuela; Kammler, Roswitha; Maibach, Rudolf; Smyth, Mark J; Di Leo, Angelo; Colleoni, Marco; Viale, Giuseppe; Regan, Meredith M; André, Fabrice.
Afiliación
  • Loi S; Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia. Electronic address: sherene.loi@petermac.org.
  • Giobbie-Hurder A; IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Gombos A; Institute Jules Bordet, Brussels, Belgium.
  • Bachelot T; Centre Léon Bérard, Lyon, France.
  • Hui R; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia.
  • Curigliano G; University of Milano, Milan, Italy; IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Campone M; Institut de Cancérologie de l'Ouest, Saint-Herblain, Nantes, France.
  • Biganzoli L; Ospedale di Prato-AUSL Toscana Centro, Prato, Italy.
  • Bonnefoi H; Institut Bergonié Comprehensive Cancer Center, Université de Bordeaux, Bordeaux, France.
  • Jerusalem G; International Breast Cancer Study Group, CHU Liège, Liège University, Liège, Belgium.
  • Bartsch R; Medical University of Vienna, Vienna, Austria.
  • Rabaglio-Poretti M; University Hospital Inselspital, Bern, Switzerland; International Breast Cancer Study Group Coordinating Center, Bern, Switzerland.
  • Kammler R; International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; International Breast Cancer Study Group and Central Pathology Office, Bern, Switzerland.
  • Maibach R; International Breast Cancer Study Group Coordinating Center, Bern, Switzerland.
  • Smyth MJ; QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
  • Di Leo A; International Breast Cancer Study Group and Ospedale di Prato-AUSL Toscana Centro, Prato, Italy.
  • Colleoni M; International Breast Cancer Study Group and Division of Medical Senology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Viale G; University of Milano, Milan, Italy; IEO, European Institute of Oncology IRCCS, Milan, Italy; International Breast Cancer Study Group and Central Pathology Office, Bern, Switzerland.
  • Regan MM; IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • André F; Institut Gustave Roussy, Université Paris Sud, INSERM U981, Villejuif, France.
Lancet Oncol ; 20(3): 371-382, 2019 03.
Article en En | MEDLINE | ID: mdl-30765258
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Anticuerpos Monoclonales Humanizados / Trastuzumab Tipo de estudio: Clinical_trials / Guideline Límite: Adolescent / Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Anticuerpos Monoclonales Humanizados / Trastuzumab Tipo de estudio: Clinical_trials / Guideline Límite: Adolescent / Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article